Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1949 1
1950 1
1952 3
1954 1
1955 1
1956 2
1957 2
1958 1
1959 1
1963 2
1964 4
1965 3
1966 2
1967 2
1970 1
1974 1
1978 1
1979 1
1980 2
1982 2
1983 3
1984 5
1985 1
1986 1
1987 1
1988 1
1989 1
1990 1
1991 1
1992 2
1997 1
2000 1
2001 4
2005 1
2007 1
2008 1
2015 2
2016 3
2017 2
2018 3
2019 1
2020 4
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

78 results
Results by year
Filters applied: . Clear all
Page 1
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
Phillips AC, Boghaert ER, Vaidya KS, Falls HD, Mitten MJ, DeVries PJ, Benatuil L, Hsieh CM, Meulbroek JA, Panchal SC, Buchanan FG, Durbin KR, Voorbach MJ, Reuter DR, Mudd SR, Loberg LI, Ralston SL, Cao D, Gan HK, Scott AM, Reilly EB. Phillips AC, et al. Among authors: reilly eb. Mol Cancer Ther. 2018 Apr;17(4):795-805. doi: 10.1158/1535-7163.MCT-17-0710. Epub 2018 Feb 26. Mol Cancer Ther. 2018. PMID: 29483208 Free article.
ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence.
Wang J, Anderson MG, Oleksijew A, Vaidya KS, Boghaert ER, Tucker L, Zhang Q, Han EK, Palma JP, Naumovski L, Reilly EB. Wang J, et al. Among authors: reilly eb. Clin Cancer Res. 2017 Feb 15;23(4):992-1000. doi: 10.1158/1078-0432.CCR-16-1568. Epub 2016 Aug 29. Clin Cancer Res. 2017. PMID: 27573171 Free article.
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
Strickler JH, Weekes CD, Nemunaitis J, Ramanathan RK, Heist RS, Morgensztern D, Angevin E, Bauer TM, Yue H, Motwani M, Parikh A, Reilly EB, Afar D, Naumovski L, Kelly K. Strickler JH, et al. Among authors: reilly eb. J Clin Oncol. 2018 Nov 20;36(33):3298-3306. doi: 10.1200/JCO.2018.78.7697. Epub 2018 Oct 4. J Clin Oncol. 2018. PMID: 30285518 Clinical Trial.
Neglect, HPA axis reactivity, and development.
Reilly EB, Gunnar MR. Reilly EB, et al. Int J Dev Neurosci. 2019 Nov;78:100-108. doi: 10.1016/j.ijdevneu.2019.07.010. Epub 2019 Jul 30. Int J Dev Neurosci. 2019. PMID: 31374220 Review.
HAEMATURIA AND ANTICOAGULANTS.
REILLY EB, PERRY A, FUJITA K, NAKAMURA RM. REILLY EB, et al. Lancet. 1964 Mar 7;1(7332):554. doi: 10.1016/s0140-6736(64)92940-x. Lancet. 1964. PMID: 14100201 No abstract available.
ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.
Phillips AC, Boghaert ER, Vaidya KS, Mitten MJ, Norvell S, Falls HD, DeVries PJ, Cheng D, Meulbroek JA, Buchanan FG, McKay LM, Goodwin NC, Reilly EB. Phillips AC, et al. Among authors: reilly eb. Mol Cancer Ther. 2016 Apr;15(4):661-9. doi: 10.1158/1535-7163.MCT-15-0901. Epub 2016 Feb 4. Mol Cancer Ther. 2016. PMID: 26846818 Free article.
78 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page